Non-Hodgkin Lymphoma Therapeutics Market Research Report 2020 Radiant Insights, Inc
GBI Research, the leading business intelligence provider, has released its latest research, 'Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting', which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL). Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-hodgkin-lymphoma-therapeutics-in-asia-pacific-markets-to-2020-novel-technologies-show-considerable-promise-in-relapsed-refractory-setting The market in the APAC region was worth an estimated $1.1 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.6% to $1.7 billion in 2020. The expected launches of promising drugs, including novel protein kinase inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Rituxan/Mabthera, will be the key growth drivers. The launch of premium-priced novel glycol-engineered antibody; obinutuzumab; kinase inhibitors including idelalisib and ibrutinib; and the mTOR inhibitor everolimus are also expected to have a significant impact, as is the anticipated approval of immunomodulatory agent Revlimid as a maintenance setting. An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC NHL market.
GBI Research, the leading business intelligence provider, has released its latest research, 'Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting', which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL).
Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-hodgkin-lymphoma-therapeutics-in-asia-pacific-markets-to-2020-novel-technologies-show-considerable-promise-in-relapsed-refractory-setting
The market in the APAC region was worth an estimated $1.1 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.6% to $1.7 billion in 2020. The expected launches of promising drugs, including novel protein kinase inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Rituxan/Mabthera, will be the key growth drivers. The launch of premium-priced novel glycol-engineered antibody; obinutuzumab; kinase inhibitors including idelalisib and ibrutinib; and the mTOR inhibitor everolimus are also expected to have a significant impact, as is the anticipated approval of immunomodulatory agent Revlimid as a maintenance setting. An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC NHL market.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Figure 2: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Treatment Algorithm for Indolent <strong>Non</strong>-<strong>Hodgkin</strong><br />
<strong>Lymphoma</strong>, 2014 22<br />
Figure 3: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Treatment Algorithm for Aggresive <strong>Non</strong>-<strong>Hodgkin</strong><br />
<strong>Lymphoma</strong>, 2014 23<br />
Figure 4: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Rituxan, Annual Sales ($bn), 2006-2013 25<br />
Figure 5: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Adcetris, Annual Sales ($m), 2011-2013 27<br />
Figure 6: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Velcade, Annual Sales ($bn), 2007-2013 30<br />
Figure 7: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Istodax, Annual Sales ($m), 2010-2013 31<br />
Figure 8: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Comparative Safety and Efficacy of <strong>Market</strong>ed<br />
Products (Heat Map), 2014 36<br />
Figure 9: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Pipeline by Stage of Development, Program Type<br />
and Route of Administration, 2014 38<br />
Read Complete <strong>Report</strong> with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-<strong>2020</strong>-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting<br />
Figure 10: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Pipeline by Molecule Type and Stage of<br />
Development, 2014 39<br />
Figure 11: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Pipeline by Mechanism of Action, 2014 40<br />
Figure 12: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong>, Global, Pipeline by Mechanism of Action, Molecule Type and<br />
Stage of Development (Number), 2014 41<br />
Figure 13: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Clinical Trial Failure Rate (%), 2014 42<br />
Figure 14: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Clinical Trial Size (Participants), 2014 43<br />
Figure 15: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Pipeline Clinical Trial Duration (Months), 2014 44<br />
Figure 16: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Global, Comparative Safety and Efficacy of Pipeline<br />
Products (Heat Map), 2014 50<br />
Figure 17: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, Asia-Pacific, <strong>Market</strong> Size, 2013-<strong>2020</strong> 52<br />
Figure 18: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, India, Treatment Usage Pattern ('000), 2013-<strong>2020</strong> 53<br />
Figure 19: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, India, Annual Cost of Therapy ($), 2013-<strong>2020</strong> 54<br />
Figure 20: <strong>Non</strong>-<strong>Hodgkin</strong> <strong>Lymphoma</strong> <strong>Market</strong>, India, <strong>Market</strong> Size ($m), 2013-<strong>2020</strong> 55
Change language